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ABSTRACT 
Rofecoxib is a specific COX-2 inhibitor able to exert antiproliferative activity against colorectal 
cancer cells. It was withdrawn from the market after the demonstration of an increased risk of 
cardiovascular complications after prolonged use. Nevertheless it remains an interesting compound 
for laboratory research as an experimental COX-2 inhibitor. In the present study the 
antiproliferative activity of a novel dinitro-oxy-substituted analogue of rofecoxib (NO-rofe), 
potentially less cardiotoxic, has been investigated in vitro on human colon cancer cells and 
compared with the action of the parent drug. Due to the fact that COX-2 inhibition is the main 
characteristic of coxibs we performed all experiments in COX-2-overexpressing (HT-29) and COX-
2-negative (SW-480) human colon cancer cells, in order to elucidate whether the observed effects 
were dependent on COX-2 inhibition. Moreover, experiments were performed in order to evaluate 
whether COX-2 pharmacological inhibition may affect beta-catenin/E-cadherin signalling pathway. 
NO-rofe exerted a significant antiproliferative activity on COX-2 positive HT-29 human colon 
cancer cells, being less effective on the COX-2 negative SW-480 human colon cancer cell line. In 
particular, the rofecoxib analogue retained similar potencies with respect to COX-2 inhibition but 
was much more active than rofecoxib in inhibiting the growth of human colon cancer cells in vitro. 
In addition, this novel compound resulted in the induction of membrane β-catenin/E-cadherin 
expression, a feature that may significantly contribute to its antiproliferative activity. 
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INTRODUCTION 
Epidemiological, animal and cell culture studies have shown chemopreventive and tumor-regressive 
effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer [1]. A large body of 
evidence indicate that regular use of NSAIDs reduces the relative risk of developing colorectal 
cancer [2], leading to regression of pre-existing adenomas in patients with familial adenomatous 
polyposis and preventing recurrence of sporadic colonic adenomas [3,4]. However, the prolonged 
use of NSAIDs is associated with side effects such as gastritis, peptic ulcer, gastrointestinal 
bleeding, and/or perforation of gastroduodenal ulcers [5]. The anti-inflammatory and antitumor 
effects of NSAIDs have been, at least partially, attributed to the inhibition of the inducible 
cyclooxygenase (COX)-2, while unwanted side effects of these drugs arise from the inhibition of 
the constitutive COX-1 [6]. Deregulation of the COX-2 pathway appears to affect tumorigenesis via 
a number of distinct mechanisms: promoting tumour maintenance and progression, favoring 
metastatic spread, and perhaps even participating in tumour initiation [7]. As such, COX-2-selective 
inhibitors typified by rofecoxib, celecoxib and valdecoxib [8] were developed to reduce the incidence of 
gastrointestinal side effects associated with non-selective long-term inhibition of COX-1 and COX-
2 by traditional NSAIDs.  
Unfortunately, randomised clinical trials and observational studies have shown an increased risk of 
myocardial infarction, stroke, hypertension and heart failure during prolonged treatment of patients 
with highly selective COX-2 inhibitors [9,10]. The mechanisms underlying the cardiotoxicity of 
Coxibs remain a matter of active debate. It has been reported that preferential inhibition of COX-2 
in the vasculature, which might lead to an imbalance in the levels of prostacyclin and thromboxane 
in favor of thrombogenic tromboxane, could contribute to the pro-thrombotic effects of selective 
COX-2 inhibitors [11]. 
As a consequence, rofecoxib, as well as other Coxibs, was withdrawn from the market because of 
increased risk of adverse cardiovascular events and metabolic complications [10]. Although 
rofecoxib has at present no therapeutic application because of toxicity concerns, nevertheless it 
remains an interesting and relevant model drug for the synthesis of COX-2 selective inhibitors. 
Along these lines, a strategy to reduce cardiotoxicity of Coxibs and to improve their benefit-risk 
profiles may result in the design of a multi-target drug able to combine COX-2 selective inhibition 
with nitric oxide (NO)-dependent activities. This, in view of the fact that NO is a key regulator of 
blood flow and an important modulator of platelet and leukocyte activation, adhesion and 
aggregation [12]. Inhibition of NO synthesis leads to an increase in systemic blood pressure (BP), 
underscoring the importance of vascular NO generation in controlling BP.  A growing number of 
evidence indicates that NO signalling is a key factor in counteracting the onset and development of 
several cardiovascular diseases including hypertension, myocardial infarction and stroke. NO also 
prevents atherogenesis by inhibiting vascular smooth muscle cell proliferation and preventing low-
density lipoprotein oxidation and macrophage activation [13]. 
NO-donor coxibs have been developed in order to both implement gastric tolerance and to reduce 
cardiotoxicity of the parent drug and examples of such an approach for drug design have already 
been reported 14-16].  
To this class of compounds belongs a new analogue of rofecoxib (NO-rofe), that has been obtained 
by introducing two nitro-oxy functions on the phenyl ring, and that has been reported to inhibit 
COX-2 isoform and to dilate rat aorta strips pre-contracted with phenylephrine [17]. 
In this study we describe a preliminary biological characterization of the  anti-proliferative activity 
of a new NO-donor and COX-2 inhibitor (NO-rofe). In order to address this specific issue we 
compared the anti-proliferative activity of rofecoxib and NO-rofe on human colon cancer cells 
either overexpressing (HT-29) or  non expressing (SW-480) COX-2 activity. 
 
 
MATERIALS AND METHODS 
Materials and reagents 
Rofecoxib was obtained from LC Laboratories (Woburn, MA, USA), whereas nitro-oxy analogue 
of rofecoxib (NO-rofe) was designed and synthesized at the Department of Scienza e Tecnologia 
del Farmaco, University of Torino, Italy (Fig. 1) [17]. The drugs were solubilized in 
dimethylsulfoxide (DMSO) (Sigma Chemical) and freshly diluted in culture medium before each 
experiment. The final DMSO concentration never exceeded 0.1% and this condition was used as 
control in each experiment. 
Rabbit polyclonal antibodies raised against c-myc and ERK1, mouse monoclonal antibody  raised 
against E-cadherin, β-catenin and phospho-ERK1/2 as well as goat anti-rabbit and goat anti-mouse 
secondary antibodies were obtained from Santa Cruz Biotechnology Inc. (CA, USA). Rabbit 
polyclonal antibody raised against COX-2 and COX-2 purified protein was from Cayman Chemical 
(Michigan, USA). Enhanced chemiluminescence (ECL) detection system was from Amersham 
Pharmacia Biotech (Uppsala, Sweden). All other reagents were purchased from Sigma Chemical 
Co. (St. Louis, MO). 
Cell line and culture conditions 
The human HT-29 and SW-480 colon cancer cell lines were obtained from American Type Cell 
Culture (Manassas, VA, USA) and were grown and amplified at 37 °C in a humidified 5% CO2 
environment in McCOY'S 5A (HT-29) and DMEM (SW-480) medium supplemented with 10% 
foetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 25 μg/ml amphotericin B.  
For the experiments, cells were seeded at a density of 3 × 10
4
 cells/cm
2
 and cultured for 24 h to 
allow them to adhere to the substratum and then treated with either test compounds or DMSO. 
Viability assay 
Cells were seeded in 12-well culture plates and properly treated. Aliquots of cell suspension were 
incubated with trypan blue solution (0.5% in NaCl) for 5 min to assess cell viability. Finally, cells 
were transferred to the Bürker chamber and counted by light microscope. Dead cells were defined 
as those stained with the dye. IC50 values (concentration that caused 50% inhibition of growth) were 
calculated from a graph using SigmaPlot software. 
Total extracts 
Cells were seeded in 75 cm
2
 plates and properly treated. Cells were suspended in lysis buffer 
containing 20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid 
(EDTA), 0.1 mM phenylmethyl-sulfonyl fluoride (PMSF), 0.05% aprotinin, 0.1% igepal and then 
incubated for 30 min at 4 °C. The suspension was centrifuged for 25 min at 12,000 rpm and the 
supernatant from this centrifugation was saved as the total extracts. 
Membrane-associated fractions 
Cells were seeded in 75 cm
2
 plates and properly treated. Cells were suspended in hypotonic buffer 
containing 10 mM Tris (pH 7.4), 0.2 mM MgCl2, 2 μg/ml pepstatin A, 2 μg/ml leupeptin and 
100 μg/ml PMSF for 10 min on ice and then homogenized with a Dounce homogenizer. The 
homogenates were centrifuged for 37 min at 20,750 rpm; the resulting precipitate was analysed as 
the membrane-associated fraction. 
Western blot analysis 
Protein content was evaluated using the Protein Assay Kit 2 (Bio-Rad Laboratory, Hercules, CA). 
Equal amounts of proteins (50 µg) were mixed with solubilization buffer containing 250 mM Tris 
(pH 8.8), 4% sodium dodecyl sulfate (SDS), 16% glycerol, 8% 2-mercaptoethanol and 0.1% 
bromophenol blue, and then fractionated by electrophoresis on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred onto nitrocellulose for 
2 h in a Biorad electro-blotting device. Nitrocellulose matrices were blocked with 5% milk in TBST 
(1 M Tris buffer saline, pH 7.4, 5 M NaCl, 0.1% Tween-20) for 1 h at room temperature. For 
immunodetection, matrices were incubated overnight at 4 °C with primary antibody. The matrices 
were then detected by incubation for 1 h at room temperature with the corresponding horseradish 
peroxidase-conjugated secondary antibody. The immunoreactive bands were visualized using the 
ECL system. Band intensities were quantified by densitometry and expression of proteins was 
reported as a proportion of β-actin or ERK1 protein expression to control for any discrepancies in 
gel loading. Fold change versus control values has been calculated by normalizing densitometric 
values obtained from the various proteins with those obtained for β-actin or ERK1 (VersaDoc 
Imaging System 3000, Biorad). 
Statistical analysis 
Differences between the means were analyzed for significance using the one-way ANOVA test with 
Bonferroni post hoc multiple comparisons, used to assess the differences between independent 
groups. All values are expressed as means ± SD, and differences were considered significant at 
p<0.05. 
 
 
RESULTS AND DISCUSSION 
As a first experimental approach, we examined the sensitivity of the COX-2 positive (HT-29) and 
negative (SW-480) colon cancer cell lines to rofecoxib and to its nitro-oxy derivative (NO-rofe).  
HT-29 cells were found to be more sensitive to the anti-proliferative effects of the drugs than SW-
480 cells. Increasing concentrations of NO-rofe decreased dramatically HT-29 cell growth in a 
time- and dose-dependent manner (figure 1B). The IC50 values (i.e., concentration that produced 
50% inhibition of the growth) for NO-rofe was 35.9 µM at 24 h, 19.6 µM at 48 h and 9.6 µM at 
72h. Rofecoxib only marginally affected the growth of HT-29 cells (10-25% at 50 μM) (figure 1A), 
making impossible to calculate IC50 values. It is interesting to note the co-treatment of this cell line 
with NO-rofe and the NO scavenger carboxy-PTIO (cPTIO) completely reverted the inhibitory 
effect on cell viability  (figure 1C).  
Although a slight degree of growth inhibition was observed in SW-480 cells, these cells were barely 
sensitive to both compounds according to their lack of COX-2 expression (figure 1D).  
According to cell viability data, both NO-rofe and, to a lesser extent, rofecoxib resulted in a 
decreased phosphorylation/activation of ERK1/2 and expression of the transcription factor c-myc 
only in COX-2-overexpressing HT-29 cells (figure 2A), with no significant effects observed in 
COX-2-negative SW-480 cells (figure 2B). When HT-29 cells were co-treated with NO-rofe and 
the NO scavenger this experimental approach did not result in a complete reversion of the effects on 
ERK1/2 phosphorylation state and c-myc protein levels (figure 2A), supporting the hypothesis that 
the drugs may down-regulate  proliferation by affecting the COX-2 pathway.  
The role of COX-2 was then further investigated in order to analyse its involvement in growth 
inhibition. As expected, in HT-29 cells rofecoxib and NO-rofe down-regulated the expression of 
intracellular COX-2 protein levels (approx. 45% inhibition) to a very similar and significant extent 
(figure 2A). According to literature data [18], no significant change in COX-2 protein level was 
observed in COX-2 negative SW-480 cells (data not shown).  
COX-2 activity was also analysed by evaluating prostaglandin E2 (PGE2) concentration in HT-29 
cells. Both rofecoxib and NO-rofe, employed at 50 µM concentration, significantly decreased PGE2 
synthesis to no more than 40% of control values (data not shown).  
Along these lines, it is known that PGE2, through the stimulation of EP2 receptor, leads to the   
inactivation of GSK-3β, leading in turn to β-catenin accumulation in the nucleus and to the 
increased transcription of its target genes [19]. β-catenin, which is overexpressed in nearly all 
colorectal carcinomas, is known to function as a transcription factor involved in oncogenic signal 
transduction thereby strongly promoting tumor growth and impairing patient survival [20].  
Previous studies from our [16] and other laboratories [21] have shown that suppression of β-
catenin-mediated signal transduction represents a major pharmacological mechanism of the COX-2 
selective inhibitor celecoxib  which is responsible for its chemopreventive effect.  
In the present study, in agreement with other literature data [22], we found that rofecoxib exerted 
only a negligible effect on the membrane expression of β-catenin and E-cadherin (figure 2A), 
indicating that the modulation of β-catenin system may not represent a general effect common to all 
coxibs. 
Whether NO-rofe was concerned, this drug potently induced β-catenin and E-cadherin membrane 
expression, increasing the amount of β-catenin available to form complexes with E-cadherin (figure 
2A); of interest, the NO scavenger was able to significantly reduce both of these effects. This 
finding is potentially relevant since down-regulation of E-cadherin is currently believed to play a 
role in tumour invasion, which requires the ability of cells to spread to distant sites and is associated 
with reduced cell–cell adhesion [23]. These results, together with the fact that in SW-480 cells only 
NO-rofe retains the ability to induce the expression of both β-catenin and E-cadherin (figure 2B), 
seem to confirm that COX-2 inhibition may significantly contribute to the anti-proliferative efficacy 
of this drug while the presence of the nitro-oxy function is more likely involved in the modulation 
of β-catenin/E-cadherin system, modulation that appears then as COX-2 independent.  
These data are in accordance with results obtained from our previous work, in which we evaluated 
the biological effects of a novel nitro-oxy derivative of celecoxib in human colon cancer cells with 
the aim to elucidate whether these properties may depend on COX-2 inhibition and/or NO-release. 
The overall final results from this study indicated that the nitro-oxy derivative behaved like 
celecoxib in terms of COX-2 inhibition, while the benzyl nitrate had no such effects; on the 
contrary, the ß-catenin system was activated by the nitro-oxy derivative as well as by benzyl nitrate 
alone more potently than the parent compound celecoxib, suggesting a possible regulatory role for 
NO [24]. 
CONCLUSIONS 
Our preliminary results suggest that NO-rofe can display its activity through both COX-2 inhibition 
and NO-donating property. This compound retains similar potencies with respect to COX-2 activity 
inhibition but is much more active than rofecoxib in inhibiting the growth of human colon cancer 
cells in vitro. In addition, the strong induction of membrane β-catenin/E-cadherin expression may 
represent an important contributing factor to the antitumor activity of this selective COX-2 
inhibitor. As a matter of fact, overexpression of membrane E-cadherin and β-catenin caused by NO-
rofe could negatively affect cell migration and tumour invasiveness, as already shown for other 
COX-2 inhibitors [25].   
Further experimental work is needed in order to fully outline the molecular mechanisms responsible 
for the antiproliferative effect exerted by NO-rofe in order to support its use for treatment or 
chemoprevention of colon cancer. 
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FIGURE LEGENDS 
 
Figure 1. Molecular structure of rofecoxib (PM: 315.35 uma) and its nitro-oxy derivative (PM: 
386.32 uma). 
 
Figure 2. Effect of rofecoxib and NO-rofe on the growth of COX-2 positive (HT-29) and negative 
(SW-480) colon cancer cells.  
HT-29 cells were exposed for 24, 48 and 72 h to different concentrations of rofecoxib (A) and NO-
rofe (B). Untreated cells incubated in the presence of vehicle (0.1% DMSO) were used as controls.  
HT-29 (C) and SW-480 (D) cells were exposed for 24 h to 10 and 50 µM concentrations of 
compounds, with or without carboxy-PTIO. 
Cell viability was determined by the trypan blue exclusion test and calculated by standardizing 
viable untreated cells to 100%. The values represent the mean of 3 independent experiments each 
performed in triplicate (bars, SD). Statistical significance compared with untreated control: 
*P < 0.05, **P < 0.01, ***P < 0.001, by one-way ANOVA test with the Bonferroni.  
 
Figure 3.  Effect of rofecoxib and NO-rofe on COX-2, pERK, c-myc, β-catenin and E-cadherin 
expression in HT-29 and SW-480.  
HT-29 (A) and SW-480 (B) cells were exposed for 24 h to 50 µM concentration of the drugs, with 
or without carboxy-PTIO. Untreated cells incubated in the presence of vehicle (0.1% DMSO) were 
used as controls. 
Total lysates were probed with anti-COX-2, anti-pERK and anti-c-myc antibody and normalized 
with anti-ERK1/2 or anti-β-actin antibody; COX-2 purified protein was used as positive control. 
Membrane-associated fractions were probed with anti-E-cadherin and anti-β-catenin antibody and 
protein content was routinely stained using Ponceau Red dye.  
Protein contents were quantified by densitometry. A representative experiment from at least two 
independent experiments is shown. 
 
 
 
 
